The first, a non-randomized clinical trial conducted by Bayer® (Leverkusen, Germany), aims to assess the tolerability and toxicity of an AhR inhibitor, BAY2416964, on 114 patients with advanced solid tumors and no therapeutic options (lung cancer, head and neck cancer, and colorectal cancer) (NCT04069026). The gene discussed is AHR; the disease is colorectal cancer.